KR20160030076A - 인간 분비글로빈 단백질의 변형 및 신규한 조성물 - Google Patents

인간 분비글로빈 단백질의 변형 및 신규한 조성물 Download PDF

Info

Publication number
KR20160030076A
KR20160030076A KR1020157029582A KR20157029582A KR20160030076A KR 20160030076 A KR20160030076 A KR 20160030076A KR 1020157029582 A KR1020157029582 A KR 1020157029582A KR 20157029582 A KR20157029582 A KR 20157029582A KR 20160030076 A KR20160030076 A KR 20160030076A
Authority
KR
South Korea
Prior art keywords
chemically
globin
composition
rhcc10
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157029582A
Other languages
English (en)
Korean (ko)
Inventor
에이프릴 엘. 필론
훔차 케이. 하리프라카샤
리차드 에스. 클레이턴
멜리사 이. 윈
Original Assignee
쎄라브론 쎄라퓨틱스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쎄라브론 쎄라퓨틱스, 아이엔씨. filed Critical 쎄라브론 쎄라퓨틱스, 아이엔씨.
Publication of KR20160030076A publication Critical patent/KR20160030076A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
KR1020157029582A 2013-03-15 2014-03-17 인간 분비글로빈 단백질의 변형 및 신규한 조성물 Ceased KR20160030076A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,773 US9394349B2 (en) 2013-03-15 2013-03-15 Modification and compositions of human secretoglobin proteins
US13/843,773 2013-03-15
PCT/US2014/030117 WO2014145368A2 (en) 2013-03-15 2014-03-17 Modification and novel compositions of human secretoglobin proteins

Publications (1)

Publication Number Publication Date
KR20160030076A true KR20160030076A (ko) 2016-03-16

Family

ID=51530119

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029582A Ceased KR20160030076A (ko) 2013-03-15 2014-03-17 인간 분비글로빈 단백질의 변형 및 신규한 조성물

Country Status (13)

Country Link
US (4) US9394349B2 (enExample)
EP (2) EP2968449A4 (enExample)
JP (2) JP6670987B2 (enExample)
KR (1) KR20160030076A (enExample)
CN (1) CN105744946A (enExample)
AU (1) AU2014233127A1 (enExample)
BR (1) BR112015021266A2 (enExample)
CA (1) CA2907439A1 (enExample)
IL (1) IL241417A0 (enExample)
MX (1) MX2015013092A (enExample)
RU (1) RU2015144360A (enExample)
SG (1) SG11201507277YA (enExample)
WO (1) WO2014145368A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162914B2 (en) 2013-03-15 2024-12-10 Apc Research Assets Llc Modification and compositions of human secretoglobin proteins
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
AU2015369776A1 (en) * 2014-12-22 2017-06-15 The Regents Of The University Of California Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
US11690893B2 (en) 2018-11-30 2023-07-04 Apc Research Assets Llc Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006919A3 (nl) * 1993-03-15 1995-01-24 Ley Marc Jozef Philemon De Farmaceutisch preparaat op basis van clara celeiwit cc10, en het gebruik daarvan als geneesmiddel en diagnosticum.
US20040047857A1 (en) * 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
WO2000009741A1 (en) 1998-08-13 2000-02-24 The Trustees Of The University Of Pennsylvania Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (ja) 2003-05-14 2004-11-25 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の検出方法
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
CN1580261A (zh) * 2003-08-06 2005-02-16 上海富纯中南生物技术有限公司 Cc10蛋白的制备及应用
WO2005048993A2 (en) 2003-11-14 2005-06-02 Alza Corporation Minimization of drug oxidation in drug irradiated excipients formulations
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
KR101597391B1 (ko) * 2009-10-15 2016-02-24 클라라산스, 인크. 인플루엔자 치료용 재조합 사람 ｃｃ10 단백질
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins

Also Published As

Publication number Publication date
AU2014233127A1 (en) 2015-09-24
US20140275477A1 (en) 2014-09-18
JP2020055833A (ja) 2020-04-09
RU2015144360A (ru) 2017-04-24
JP6670987B2 (ja) 2020-03-25
WO2014145368A2 (en) 2014-09-18
CA2907439A1 (en) 2014-09-18
MX2015013092A (es) 2016-06-02
EP2968449A2 (en) 2016-01-20
US10294285B2 (en) 2019-05-21
US9394349B2 (en) 2016-07-19
BR112015021266A2 (pt) 2017-10-10
SG11201507277YA (en) 2015-10-29
JP2016515532A (ja) 2016-05-30
US10676513B2 (en) 2020-06-09
WO2014145368A3 (en) 2014-11-27
EP3403666A1 (en) 2018-11-21
US20200325190A1 (en) 2020-10-15
US20160362462A1 (en) 2016-12-15
CN105744946A (zh) 2016-07-06
US20190337999A1 (en) 2019-11-07
EP2968449A4 (en) 2017-03-22
IL241417A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
US10676513B2 (en) Modification and compositions of human secretoglobin proteins
Souza et al. Dityrosine cross-linking promotes formation of stable α-synuclein polymers: implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies
Li et al. Identification of two prokineticin cDNAs: recombinant proteins potently contract gastrointestinal smooth muscle
Allen Sequencing of proteins and peptides
AU2018215245A1 (en) Interaction between C-peptides and elastin receptor, a model for understanding vascular disease
CN105849123A (zh) 蛋白酶抗性肽
CN108271373A (zh) 蛋白酶抗性脂化glp-1类似物
El‐Desoky et al. Chemical synthesis of insulin‐like peptide 1 and its potential role in vitellogenesis of the kuruma prawn Marsupenaeus japonicus
Pozzi et al. Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis
Gangadhariah et al. Hydroimidazolone modification of human αA-crystallin: Effect on the chaperone function and protein refolding ability
HIRABAYASHI et al. Further characterization and structural studies on human placenta lectin
Perdikoulis et al. Expression and characterisation of the thrombospondin type I repeats of human properdin
Dietrich et al. Serine protease inhibitor Kazal-type 2 is expressed in the male reproductive tract of carp with a possible role in antimicrobial protection
Jelı́nková et al. Proteinase inhibitors in aggregated forms of boar seminal plasma proteins
US12162914B2 (en) Modification and compositions of human secretoglobin proteins
Pennypacker et al. Expression of fos-related antigen-2 in rat hippocampus after middle cerebral arterial occlusion
Lesner et al. Fluorescent analogs of trypsin inhibitor SFTI‐1 isolated from sunflower seeds—synthesis and applications
KR20240073156A (ko) 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
Scott Spectroscopic study of environment-dependent changes in the conformation of the isolated carboxy-terminal telopeptide of type I collagen
Słowińska et al. Isolation, characterization and cDNA sequencing of a Kazal family proteinase inhibitor from seminal plasma of turkey (Meleagris gallopavo)
Sardana et al. Chemical modification and cross-linking of neurophysin tyrosine-49
Reeder et al. Histidine and not tyrosine is required for the Peroxide‐induced formation of haem to protein cross‐linked myoglobin
Surin et al. The effect of MII α-conotoxin and its N-terminal derivatives on Ca2+-and Na+-signals induced by nicotine in SH-SY5Y neuroblastoma cells
JP2012051826A (ja) 環状ペプチド及びその修飾ペプチド並びにＫｅｌｃｈ様ＥＣＨ結合タンパク質１の結合阻害物質のスクリーニング方法
Arii et al. Production of a soluble recombinant prion protein fused to blue fluorescent protein without refolding or detergents in Escherichia coli cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190318

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200623

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210127

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200623

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I